ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today that it will present at the 29 th Annual J.P. Morgan Healthcare Conference at 2 p.m.

Net Sales of $53.4 Million , International Sales Rise 12% Net Income of $3.3 Million , or $0.13 EPS Gross Margin of 59.1% Operating Cash Flow of $9.9 Million Reiterates Fiscal Year 2011 Guidance Conference Call Today at 4:30 p.m. Eastern Time ALBANY, N.Y.

ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today announced that it will report its fiscal 2011 second quarter financial results on Tuesday, January 4,

ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today announced that it will present at the 5th Annual Canaccord Genuity Cardiovascular, Diabetes and

ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today announced that it will present at the Stephens Inc. Fall Investment Conference at 1:30 p.m.

ALBANY, N.Y., Nov 01, 2010 (BUSINESS WIRE) -- In the first graph, first sentence of release dated Oct. 25, 2010, the conference presentation time is incorrect. It should read: 2:45 p.m. ET (sted 4:30 p.m. ET). The corrected release reads: ANGIODYNAMICS TO PARTICIPATE AT THE 21ST ANNUAL OPPENHEIMER

ALBANY, N.Y., Oct 28, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today announced that Kevin J. Gould, 56, was elected to its Board of Directors at the Company's

ALBANY, N.Y., Oct 25, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today announced that it will present at the 21 st Annual Oppenheimer Healthcare Conference at

<ul>
<li class="bwlistitemmargb">
<i><b>Net Sales of $51.5 Million</b></i>
</li>
<li class="bwlistitemmargb">
<i><b>Net Income of $1.9 Million, or $0.08 EPS</b></i>
</li>
<li class="bwlistitemmargb">
<i><b>Operating Cash Flow of $1.7 Million</b></i>
</li>
<li class="bwlistitemmargb">
<i><b>Updates Fiscal Year 2011 Guidance</b></i>
</li>
<li class="bwlistitemmargb">
<i><b>Conference Call Today at 4:30 p.m. Eastern Time</b></i>
</li>
</ul>

ALBANY, N.Y., Sep 28, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today announced that it will report its fiscal 2011 first quarter financial results on

ALBANY, N.Y., Sep 14, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ: ANGO) today announced the appointment of Scott Solano as Senior Vice President and Chief Technology Officer, and Scott Etlinger to the position of Senior Vice President, Global Operations. Mr.

ALBANY, N.Y., Sep 09, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today announced that management will present at upcoming investor conferences during the month

ALBANY, N.Y., Sep 07, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO) , a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today reported preliminary unaudited results for its fiscal 2011 first quarter ended August

<i><b>New Access System Cuts Number of Procedure Steps in Half for
Varicose Vein Treatment</b></i>

ALBANY, N.Y., Aug 03, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today that it will present at the 30 th Annual Canaccord Genuity Growth Conference in

<ul>
<li class="bwlistitemmarginbottom">
<i><b>Fourth Quarter Net Sales Increase 14% to $60.3 Million</b></i>
</li>
<li class="bwlistitemmarginbottom">
<i><b>First $1.0 Million NanoKnife(R) IRE System Net Sales Quarter</b></i>
</li>
<li class="bwlistitemmarginbottom">
<i><b>Record $16.1 Million Operating Cash Flow Quarter</b></i>
</li>
<li class="bwlistitemmarginbottom">
<i><b>Fourth Quarter Net Income Grows 29%</b></i>
</li>
<li class="bwlistitemmarginbottom">
<i><b>Company Provides Guidance for FY 2011</b></i>
</li>
<li class="bwlistitemmarginbottom">
<i><b>Conference Call Begins Today at 4:30 p.m. Eastern Time</b></i>
</li>
</ul>

ALBANY, N.Y., Jul 12, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO) announced today the global expansion of its Smart Port CT family of power-injectable ports, featuring its patented Vortex (R) port technology - to include low-profile and mini models for repeated treatments such as

ALBANY, N.Y., Jun 17, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today that it will report its fiscal 2010 fourth quarter and full year financial

ALBANY, N.Y., May 20, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ: ANGO) today announced the appointment of Lynda Wallace, 47, as Senior Vice President of Business Development. In this capacity, Ms. Wallace will lead AngioDynamics' business development and strategic planning activities and join

<i><b>Company Now Offers Full Line of Peripherally Inserted Central
Catheters</b></i>
<br />